What is the price of Scilex Holding Company (SCLX)

The price of Scilex Holding Company (SCLX) is $5.61

What is the market cap of Scilex Holding Company (SCLX)

The market cap of Scilex Holding Company (SCLX) is $47.65M

Scilex Holding Company (SCLX) Operating Margin

Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.

Year	Operating Margin	Change
Not enough data for the provided dates.

Year

Operating Margin

Change

Not enough data for the provided dates.

Company	Operating Margin	Operating Margin Difference	Country
Eli Lilly and Company LLY.US	43.92%	-	US
Johnson & Johnson JNJ.US	26.81%	-	US
AbbVie Inc. ABBV.US	29.32%	-	US
Roche Holding AG RO.SW	26.59%	-	CH
Merck & Co., Inc. MRK.US	16.65%	-	US

Company

Operating Margin

Operating Margin Difference

Country